Global Markets Direct is a cutting-edge provider of market research and business consultancies for a wide range of customers worldwide.
A team of analytics is capable to produce all sorts of market information and carry out extensive industry research using unique data and reliable sources to let customers know who they are at the market. Global Markets Direct has profound analytical experience in researching the industries and preparing customized reports across many specific fields.
The company is distinguished by its high-quality consulting products and close inspection of the issues under study. Diligent efforts of the experts make every piece of business information an exclusive source of feasible solutions and valuable advice.
With a commitment to serve every client need, Global Markets Direct collects and interprets the materials for the analysis, uses methods of primary and secondary research and develops one of a kind data packages for global clients. They are able to cover the tones of industry-related information to assist customers in taking the right business decisions and developing their strategic plans.
Under the supervision of skillful managers and experts, business analysts produce reports that include:
- Product portfolio
- Potentially strong market reviews
- Competitive analytics
- Prospect partners
- Mergers and acquisitions project data
- Latest trends across a particular industry area
- Research and development strategies
- The analysis of new customers
- A set of remedial measures for projects
They will search for new partners and highlight the current business issues plus develop new strategies and tactical steps to help you take the lead in the industry where you operate.
Publications found:
5,853
Sort by:
Interleukin 23 (IL23) - Drugs in Development, 2021
US$ 3,000.00
Interleukin 23 (IL23) - Drugs in Development, 2021 SUMMARY Interleukin 23 (IL23) - Drugs in Development, 2021 provides in depth analysis on Interleukin 23 (IL23) targeted pipeline therapeutics. The re...
April 2021
35 pages
Interleukin 6 Receptor (IL6R) - Drugs in Development, 2021
US$ 3,000.00
Interleukin 6 Receptor (IL6R) - Drugs in Development, 2021 SUMMARY Interleukin 6 Receptor (IL6R) - Drugs in Development, 2021 provides in depth analysis on Interleukin 6 Receptor (IL6R) targeted pipel...
April 2021
55 pages
Interleukin 7 (IL7) - Drugs in Development, 2021
US$ 3,000.00
Interleukin 7 (IL7) - Drugs in Development, 2021 SUMMARY Interleukin 7 (IL7) - Drugs in Development, 2021 provides in depth analysis on Interleukin 7 (IL7) targeted pipeline therapeutics. The report p...
April 2021
30 pages
Ischemia (Cardiovascular) - Drugs in Development, 2021
US$ 2,000.00
Ischemia (Cardiovascular) - Drugs in Development, 2021 SUMMARY Ischemia (Cardiovascular) - Drugs in Development, 2021 provides an overview of the Ischemia pipeline landscape. The report provides compr...
April 2021
65 pages
Laryngeal Cancer (Oncology) - Drugs in Development, 2021
US$ 2,000.00
Laryngeal Cancer (Oncology) - Drugs in Development, 2021 SUMMARY Laryngeal Cancer (Oncology) - Drugs in Development, 2021 provides an overview of the Laryngeal Cancer pipeline landscape. The report pr...
April 2021
75 pages
Leukotriene B4 (LTB4) - Drugs in Development, 2021
US$ 3,000.00
Leukotriene B4 (LTB4) - Drugs in Development, 2021 SUMMARY Leukotriene B4 (LTB4) - Drugs in Development, 2021 provides in depth analysis on Leukotriene B4 (LTB4) targeted pipeline therapeutics. The re...
April 2021
35 pages
Lipase (EC 3.1.1.) - Drugs in Development, 2021
US$ 3,000.00
Lipase (EC 3.1.1.) - Drugs in Development, 2021 SUMMARY Lipase (EC 3.1.1.) - Drugs in Development, 2021 provides in depth analysis on Lipase (EC 3.1.1.) targeted pipeline therapeutics. The report prov...
April 2021
30 pages
Lipopolysaccharide (Endotoxin) - Drugs in Development, 2021
US$ 3,000.00
Lipopolysaccharide (Endotoxin) - Drugs in Development, 2021 SUMMARY Lipopolysaccharide (Endotoxin) - Drugs in Development, 2021 provides in depth analysis on Lipopolysaccharide (Endotoxin) targeted pi...
April 2021
45 pages
Liposarcoma (Oncology) - Drugs in Development, 2021
US$ 2,000.00
Liposarcoma (Oncology) - Drugs in Development, 2021 SUMMARY Liposarcoma (Oncology) - Drugs in Development, 2021 provides an overview of the Liposarcoma pipeline landscape. The report provides comprehe...
April 2021
80 pages
